Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shenzhen Chipscreen Received $28 Million for Cancer Drug

publication date: Jan 22, 2008

According to a government filing, Shenzhen Chipscreen Biosciences Ltd. was paid $28 million when it sold the ex-China rights to its cancer drug Chidamide to HUYA Bioscience International, LLC in October 2006. The out-licensing sale had been previously reported, but the price was not disclosed at the time. A histone deacetylase inhibitor (HDI), Chidamide is thought to regulate genetic activity including cell birth and death. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital